Neion Bio Strengthens Genome Engineering Leadership with Appointment of Colossal Biosciences Veteran Jame

"James has a rare ability to translate cutting-edge genome engineering into real-world preclinical and translational execution," said Dimi Kellari, co-founder and CEO of Neion Bio. "As we scale our platform toward commercial programs, building a leadership team with deep experience at the frontier of genetic engineering is a deliberate priority."

Dr. Kehler brings more than two decades of experience developing advanced gene-edited animal models and enabling preclinical studies for leading biotechnology and pharmaceutical organizations. His pioneering work in cloning mammals from blood was recognized as one of TIME magazine's Best Inventions of 2025.

Dr. Kehler's appointment reinforces Neion Bio's focus on advancing its genome engineering platform toward industrial-scale production of biologic medicines. His addition further strengthens the company's ability to translate scientific innovation into scalable, cost-efficient manufacturing solutions for the biotech industry.

About Neion Bio

Neion Bio Contacts:

[email protected]

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/e37518bc-d9ef-45ce-99a7-35e82f143444

https://www.globenewswire.com/NewsRoom/AttachmentNg/4f6216ab-2904-4d09-b30a-41ec33b0e03b

Market News and Data brought to you by Benzinga APIs

To add Benzinga News as your preferred source on Google, click here.